Equities

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVN:VTX since
announced
Transaction
value
Takeda Pharmaceutical Co Ltd-Xiidra 5% BusinessAnnounced08 May 201908 May 2019Announced5.18%5.30bn
IFM Tre IncDeal completed01 Apr 201901 Apr 2019Deal completed-8.91%1.58bn
CELLforCURE SASUDeal completed20 Dec 201820 Dec 2018Deal completed3.13%--
Endocyte IncDeal completed18 Oct 201818 Oct 2018Deal completed3.52%2.09bn
Data delayed at least 15 minutes, as of May 24 2019 16:30 BST.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.